LENZ Therapeutics, Inc. (LENZ)
3.16
+0.01
(+0.32%)
USD |
NASDAQ |
Oct 28, 14:35
LENZ Therapeutics Cash from Operations (Quarterly) : -38.71M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.71M |
| March 31, 2026 | -33.58M |
| December 31, 2025 | -33.02M |
| September 30, 2025 | -8.588M |
| June 30, 2025 | -11.51M |
| March 31, 2025 | -16.05M |
| December 31, 2024 | -9.078M |
| September 30, 2024 | -10.58M |
| June 30, 2024 | -15.80M |
| March 31, 2024 | -23.94M |
| December 31, 2023 | -20.97M |
| September 30, 2023 | -13.09M |
| June 30, 2023 | -13.52M |
| Date | Value |
|---|---|
| March 31, 2023 | -12.80M |
| December 31, 2022 | -22.43M |
| September 30, 2022 | -22.22M |
| June 30, 2022 | -22.09M |
| March 31, 2022 | -21.24M |
| December 31, 2021 | -15.59M |
| September 30, 2021 | -15.42M |
| June 30, 2021 | -13.78M |
| March 31, 2021 | -8.06M |
| December 31, 2020 | -5.271M |
| September 30, 2020 | -2.493M |
| June 30, 2020 | -0.953M |
| March 31, 2020 | -0.004M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Impact BioMedical, Inc. | 0.47M |
| Enveric Biosciences, Inc. | -2.444M |
| Liquidia Corp. | 80.24M |
| Aquestive Therapeutics, Inc. | -9.441M |
| ANI Pharmaceuticals, Inc. | 56.67M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 37.75M |
| Cash from Financing (Quarterly) | 0.395M |
| Free Cash Flow | -114.42M |
| Free Cash Flow Per Share (Quarterly) | -1.234 |
| Free Cash Flow to Equity (Quarterly) | -38.62M |
| Free Cash Flow to Firm (Quarterly) | -38.73M |
| Free Cash Flow Yield | -118.4% |